## **CLAIMS**

5

## 1. A compound of general formula I

$$R^{1}$$
 $R^{2}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{6}$ 

1

wherein

A is a straight or branched C<sub>2</sub>-C<sub>8</sub> alkyl chain;

X is a methylene, oxygen, sulphur or a NR<sup>7</sup> group;

is a straight or branched C<sub>1</sub>-C<sub>8</sub> alkyl or C<sub>3</sub>-C<sub>8</sub> alkenylene or C<sub>3</sub>-C<sub>8</sub> alkynylene chain, optionally substituted with CF<sub>3</sub>, phenyl, phenoxy or naphthyl, the aromatic rings optionally

substituted by one or more C<sub>1</sub>-C<sub>4</sub> alkyl, halogens,

trifluoromethyl, hydroxy or C<sub>1</sub>-C<sub>4</sub> alkoxy groups;

15  $R^2$ ,  $R^3$  are independently hydrogen, a  $C_1$ - $C_3$  alkyl chain, halogen, trifluoromethyl, hydroxy or  $C_1$ - $C_4$  alkoxy groups;

 $R^4$ ,  $R^5$  are independently hydrogen or  $C_1$ - $C_6$  alkyl;

R<sup>6</sup> is a hydrogen or a straight or branched C<sub>1</sub>-C<sub>8</sub> alkyl or linked to R<sup>5</sup> can form a five to seven membered lactam;

20  $\mathbb{R}^7$  is hydrogen or  $C_1$ - $C_6$  alkyl;

and the pharmaceutically acceptable salts thereof, with the proviso that when A is  $-CH_2CH_2$ ,  $R^1$ -X is ortho-benzylthio,  $R^2$ ,  $R^3$  and  $R^5$  are hydrogen and  $R^6$  methyl,  $R^4$  is other than hydrogen or methyl;

when A is -CH<sub>2</sub>CH<sub>2</sub>-, R<sup>1</sup>-X 4-methoxy, R<sup>2</sup> 2-methoxy, R<sup>3</sup> and R<sup>5</sup>

25 hydrogen and R<sup>6</sup> methyl, R<sup>4</sup> is other than hydrogen, and

25

when A is -CH<sub>2</sub>CH<sub>2</sub>-, R<sup>1</sup>-X 3-methoxy, R<sup>2</sup> 5-methoxy, R<sup>3</sup> and R<sup>5</sup> hydrogen and R<sup>6</sup> methyl, R<sup>4</sup> is other than hydrogen.

- 2. A compound of general formula I as defined in claim 1, where A is ethylene or propylene, X is oxygen, methylene, NH or NCH<sub>3</sub>,  $R^1$  is  $C_1$ - $C_8$  alkyl chain, optionally substituted with  $CF_3$ , phenyl or phenoxy group, where the aromatic ring in  $R^1$  is optionally substituted by one or two methoxy, fluoro, chloro or trifluoromethyl groups,  $R^2$  and  $R^3$  are hydrogen, methyl, methoxy, fluorine, chlorine or bromine,  $R^4$  and  $R^5$  are hydrogen or methyl,  $R^6$  is methyl or ethyl or linked to  $R^5$  form a five or six membered lactam.
- 10 3. A compound selected from the group consisting of:

N-2-(4-Butyloxy-benzylamino)-ethyl-acetamide;

N-2-[4-(4-triFluorobutyloxy)-benzylamino]-ethyl-acetamide;

N-2-(4-Pentyloxy-benzylamino)-ethyl-acetamide;

N-2-[4-(5-triFluoropentyloxy)-benzylamino]-ethyl-acetamide;

N-2-(2-Benzyloxy-benzylamino)-ethyl-acetamide;

N-2-(3-Benzyloxy-benzylamino)-ethyl-acetamide;

N-2-(4-Benzyloxy-benzylamino)-ethyl-acetamide;

N-2-[4-(5-Phenyl-pentyloxy)-benzylamino]-ethyl-acetamide;

N-2-[4-(2-Phenethyl)-benzylamino]-ethyl-acetamide;

N-{2-[2-(2-Fluoro-benzyloxy)-benzylamino]-ethyl}-acetamide;

N-{2-[3-(2-Fluoro-benzyloxy)-benzylamino]-ethyl}-acetamide;

N-{2-[4-(2-Fluoro-benzyloxy)-benzylamino]-ethyl}-acetamide;

N-{2-[4-(2-Fluoro-benzyloxy)-2-methoxy-benzylamino]-ethyl}-acetamide;

N-{2-[4-(2-Fluoro-benzyloxy)-2-methyl-benzylamino]-ethyl}-acetamide;

N-{2-[4-(2-Fluoro-benzyloxy)-3-fluoro-benzylamino]-ethyl}-acetamide;

N-{2-[4-(2-Fluoro-benzyloxy)-3-chloro-benzylamino]-ethyl}-acetamide;

N-{2-[4-(2-Fluoro-benzyloxy)-3-methoxy-benzylamino]-ethyl}-acetamide;

 $N-\{2-[4-(2-Fluoro-benzyloxy)-3-methyl-benzylamino]-ethyl\}-acetamide; \\ .$ 

10

15

20

25

```
N-{2-[4-(2-Fluoro-benzyloxy)-3,5-dimethoxy-benzylamino]-ethyl}-
acetamide;
     N-{2-[4-(2-Fluoro-benzyloxy)-3,5-dimethyl-benzylamino]-ethyl}-
acetamide;
     N-{2-[4-(2-Fluoro-benzyloxy)-3-bromo-5-methoxy-benzylamino]-
ethyl}-acetamide;
      N-3-(4-Pentyloxy-benzylamino)-propyl-acetamide;
      N-2-[4-(5-trifluoropentyloxy)-benzylamino]-propyl-acetamide;
      N-3-(4-Benzyloxy-benzylamino)-propyl-acetamide;
      N-3-[4-(2-Phenethyl)-benzylamino]-propyl-acetamide;
      N-3-[4-(5-Phenyl-pentyloxy)-benzylamino]-propyl-acetamide;
      N-{3-[4-(2-Fluoro-benzyloxy)-2-methoxy-benzylamino]-propyl}-
acetamide;
      N-{3-[4-(2-Fluoro-benzyloxy)-2-methyl-benzylamino]-propyl}-acetamide;
      N-{3-[4-(2-Fluoro-benzyloxy)-3-fluoro-benzylamino]-propyl}-acetamide;
      N-{3-[4-(2-Fluoro-benzyloxy)-3-chloro-benzylamino]-propyl}-acetamide;
      N-{3-[4-(2-Fluoro-benzyloxy)-3-methoxy-benzylamino]-propyl}-
 acetamide;
      N-{3-[4-(2-Fluoro-benzyloxy)-3-methyl-benzylamino]-propyl}-acetamide;
      N-{3-[4-(2-Fluoro-benzyloxy)-3,5-dimethoxy-benzylamino]-propyl}-
 acetamide;
       N-{3-[4-(2-Fluoro-benzyloxy)-3,5-dimethyl-benzylamino]-propyl}-
 acetamide;
       N-{3-[4-(2-Fluoro-benzyloxy)-3-bromo-5-methoxy-benzylamino]-
 propyl}-acetamide;
       1-[2-(4-Butyloxy-benzylamino)-ethyl]-pyrrolidin-2-one;
       1-{2-[4-(4-triFluorobutyloxŷ-benzylamino]-ethyl}-pyrrolidin-2-one;
```

1-[2-(4-Pentyloxy-benzylamino)-ethyl]-pyrrolidin-2-one;

```
1-{2-[4-(5-triFluoropentyloxy-benzylamino]-ethyl}-pyrrolidin-2-one;
          1-[2-(2-Benzyloxy-benzylamino)-ethyl]-pyrrolidin-2-one;
          1-[2-(3-Benzyloxy-benzylamino)-ethyl]-pyrrolidin-2-one;
          1-[2-(4-Benzyloxy-benzylamino)-ethyl]-pyrrolidin-2-one;
           1-[2-(4-Benzylthio-benzylamino)-ethyl]-pyrrolidin-2-one;
5
           1-[2-(4-Benzylamino-benzylamino)-ethyl]-pyrrolidin-2-one;
           1-{2-[4-(5-Phenyl-pentyloxy)-benzylamino]-ethyl}-pyrrolidin-2-one;
           1-{2-[4-(2-Phenoxy-ethoxy)-benzylamino]-ethyl}-pyrrolidin-2-one;
           1-{2-[4-(Naphthalen-1-ylmethoxy)-benzylamino]-ethyl}-pyrrolidin-2-one;
           1-{2-[2-(3-Fluorobenzyloxy)-benzylamino]-ethyl}-pyrrolidin-2-one;
10
           1-{2-[3-(3-Fluorobenzyloxy)-benzylamino]-ethyl}-pyrrolidin-2-one;
           1-{2-[4-(3-Fluorobenzyloxy)-benzylamino]-ethyl}-pyrrolidin-2-one;
           1-{2-[4-(4-tert-Butyl-benzyloxy)-benzylamino]-ethyl}-pyrrolidin-2-one;
           1-{2-[4-(4-triFluoromethyl-benzyloxy)-benzylamino]-ethyl}-pyrrolidin-
15
     2-one;
           1-{2-[4-(2,6-Dichloro-benzyloxy)-benzylamino]-ethyl}-pyrrolidin-2-one;
           1-{2-[4-(3,5-Dimethoxy-benzyloxy)-benzylamino]-ethyl}-pyrrolidin-2-one;
           1-{2-[4-(2-Fluoro-benzyloxy)-2-methoxy-benzylamino]-ethyl}-
     pyrrolidin-2-one;
            1-{2-[4-(2-Fluoro-benzyloxy)-2-methyl-benzylamino]-ethyl}-
20
      pyrrolidin-2-one;
            1-{2-[4-(2-Fluoro-benzyloxy)-3-fluoro-benzylamino]-ethyl}-pyrrolidin-
      2-one:
            1-{2-[4-(2-Fluoro-benzyloxy)-3-methoxy-benzylamino]-ethyl}-
      pyrrolidin-2-one;
25
            1-{2-[4-(2-Fluoro-benzyloxy)-3-methyl-benzylamino]-ethyl}-
      pyrrolidin-2-one;
            1-{2-[4-(2-Fluoro-benzyloxy)-3-chloro-benzylamino]-ethyl}-pyrrolidin-
```

```
2-one;
```

15

1-{2-[4-(2-Fluoro-benzyloxy)-3,5-dimethoxy-benzylamino]-ethyl}-pyrrolidin-2-one;

1-{2-[4-(2-Fluoro-benzyloxy)-3,5-dimethyl-benzylamino]-ethyl}-pyrrolidin-2-one;

1-{2-[4-(2-fluoro-benzyloxy)-3-bromo-5-methoxy-benzylamino]-ethyl}-pyrrolidin-2-one;

1-[3-(4-Pentyloxy-benzylamino)-propyl]-pyrrolidin-2-one;

1-[3-(2-Benzyloxy-benzylamino)-propyl]-pyrrolidin-2-one;

1-[3-(3-Benzyloxy-benzylamino)-propyl]-pyrrolidin-2-one;

1-[3-(4-Benzyloxy-benzylamino)-propyl]-pyrrolidin-2-one;

1-{3-[4-(5-Phenyl-pentyloxy)-benzylamino]-propyl}-pyrrolidin-2-one;

1-{3-[4-(2-Phenoxy-ethoxy)-benzylamino]-propyl}-pyrrolidin-2-one;

1-{3-[4-(Naphthalen-1-ylmethoxy)-benzylamino]-propyl}-pyrrolidin-2-one;

1-{3-[4-(4-tert-Butyl-benzyloxy)-benzylamino]-propyl}-pyrrolidin-2-one;

1-{3-[4-(4-triFluoromethyl-benzyloxy)-benzylamino]-propyl}-pyrrolidin-2-one;

1-{3-[4-(2,6-Dichloro-benzyloxy)-benzylamino]-propyl}-pyrrolidin-2-one;

1-{3-[4-(3,5-Dimethoxy-benzyloxy)-benzylamino]-propyl}-pyrrolidin-

20 2-one;

1-{3-[4-(2-Fluoro-benzyloxy)-2-methoxy-benzylamino]-propyl}-pyrrolidin-2-one;

1-{3-[4-(2-Fluoro-benzyloxy)-2-methyl-benzylamino]-propyl}-pyrrolidin-2-one;

25 1-{3-[4-(2-Fluoro-benzyloxy)-3-fluoro-benzylamino]-propyl}pyrrolidin-2-one;

1-{3-[4-(2-Fluoro-benzyloxy)-3-methoxy-benzylamino]-propyl}-pyrrolidin-2-one;

15

20

1-{3-[4-(2-Fluoro-benzyloxy)-3-methyl-benzylamino]-propyl}-pyrrolidin-2-one;

1-{3-[4-(2-Fluoro-benzyloxy)-3-chloro-benzylamino]-propyl}-pyrrolidin-2-one;

1-{3-[4-(2-Fluoro-benzyloxy)-3,5-dimethoxy-benzylamino]-propyl}-pyrrolidin-2-one;

1-{3-[4-(2-Fluoro-benzyloxy)-3,5-dimethyl-benzylamino]-propyl}-pyrrolidin-2-one;

1-{3-[4-(2-fluoro-benzyloxy)-3-bromo-5-methoxy-benzylamino]-10 propyl}-pyrrolidin-2-one;

or pharmaceutically acceptable salts thereof.

- 4. A process for the preparation of a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, the process comprising:
  - a) reaction of compounds of formula II

 $\mathbb{R}^{1}$   $\mathbb{R}^{2}$   $\mathbb{R}^{2}$   $\mathbb{R}^{3}$   $\mathbb{C}$   $\mathbb{R}^{3}$ 

II

wherein  $R^1$ ,  $R^2$ ,  $R^3$  and X are as defined above with compounds of formula III, in the presence of a reducing agent

wherein R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and A are as defined previously thus obtaining a

compound of formula I; or

## b) reaction of compounds of formula IV

$$\mathbb{R}^{1}$$
 $\mathbb{R}^{2}$ 
 $\mathbb{C}\mathbb{H}_{2}\mathbb{Y}$ 

IV

5

10

wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and X are as defined above and Y is a halogen atom or a O-EWG group, where the EWG means an electron withdrawing group, like e.g. mesyl, tosyl or trifluoroacetyl groups, able to transform the oxygen which they are linked to, in a good leaving group

with compounds of formula III thus obtaining a compound of formula I; or

## c) reacting of a compound of formula Ia

$$R^{1}$$
 $X$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{6}$ 
 $R^{6}$ 

15

Ia

wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup> and R<sup>6</sup>, X and A are as defined above, with compounds of formula V or VI

 $R^4Y$   $R^8CHO$  20 V VI

wherein Y is as defined above;  $R^4$  is a  $C_1$ - $C_6$  alkyl and  $R^8$  is hydrogen or  $C_1$ - $C_5$  alkyl, thus obtaining a compound of the invention in which  $R^4$  is  $C_1$ - $C_6$  alkyl; and, if desired, converting a compound of the invention into

another compound of the invention and/or, if desired, converting a compound of the invention into a pharmaceutically acceptable salt and/or, if desired, converting a salt into a free compound and/or, if desired, separating a mixture of isomers of compounds of the invention into a single isomer.

- 5. A pharmaceutical composition containing a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof in admixture with a suitable carrier and/or diluent and optionally to other therapeutic agents.
  - 6. A compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, for use as an active therapeutic substance.
- 7. The use of a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament having sodium and/or calcium channel modulating activity.